Predictors of Response to Treatment of Nephritis Adults in lupus patients biopsied Clinic Coast Barranquilla (Atlántico, Colombia) over the period 2008-2014
DOI:
https://doi.org/10.18041/2390-0512/bioc..2.2657Keywords:
Systemic lupus erythematosus, Lupus nephritis, Treatmen, Predictors factorsAbstract
Objetive: To characterize the behavior of predictors of response to treatment of lupus nephritis in adult patients biopsied at the Clinica de la Costa in the period 2008-2014. Material and Methods: A retrospective cohort of 57 patients with systemic lupus erythematous (SLE) and lupus nephritis (LN) confirmed by biopsy, classified according to the International Society of Nephrology / Renal Pathology Society (ISN / RPS) 2003 were analyzed variables were correlated Clinical and laboratory potential predictive value of therapeutic response at 12 and 24 months. Results: The study population consists of 57 female patients (91%) and men (9%), with an average age of 17.6 ± 34.5 years. Of the patients 17 (29.8%) achieved partial or complete at 12 months (8.8% complete and 22.8% partial) remission. At 24 months, 62.3% of patients achieved response (partial or complete). 84% of SLE patients had renal involvement in the first five years; histological type found were: IV (68.7%), III (19.2%), II (8.7%) and V (3.5%). In the multivariate analysis associated with treatment failure baseline creatinine greater than 1.2 mg / dl (p = 0.008975), nephrotic range proteinuria (p = 0.007) and proliferative form of NL class IV (p = 0.05). Conclusion: nephrotic-range proteinuria, lupus nephritis class IV and creatinine greater than 1.2 mg /dl at diagnosis were associated with treatment failure at 12 and 24 months.
Downloads
References
2. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004; 50(8):2559-68.
3. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54(8):2550-7.
4. Ward MM. Examining health disparities in systemic lupus erythematosus. Arthritis Rheum. 2001; 44(12):2711-4.
5. Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005; 16(4):1076-84.
6. Molina JF, Drenkard C, Molina J, Cardiel M, Uribe O, et al. Lupus eritematoso sistémico en hombres: Un estudio de 107 pacientes latinoamericanos. Medicine 1996; 75:124-9.
7. Ramos-Casals, Franco JF. Nefropatía lúpica: implicaciones de una larga evolución. Revista Clínica Española. 2001; 201(9).
8. Miranda-Hernández D, Cruz-Reyes C, Ángeles U, Jara LJ, Saavedra MA. Predictores de respuesta al tratamiento en pacientes con nefritis lúpica. Reum Clin. 2013; 1-6.
9. Aroca G, Beltrán N, Iglesias A, Laborde C, Cadena A. Comportamiento de la nefropatia lúpica durante los años 2000 a 2006. Clínica de la Costa Ltda. Barranquilla. Revista Electrónica Médica de la Costa. 2007; 2:20-5.
10. Pastén R, Massardo L, Rosenberg H, Radrigán F, et al. Nefritis lúpica membranosa pura. Rev Med Chile 2005; 133:23-32.
11. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and Eu-ropean Renal Association-European Dialysis and Transplant Association (EULAR/ERA-ED-TA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71(11):1771-82.
12. Hahn BH, McMahon M , Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64(6):797-808.
13. Alonso L, Naranjo G, Alberto L, Gómez R. Lupus eritematoso sistémico de inicio tardío. 2008; 15(3):168-85.
14. Moisés D, Maury S, Restrepo M, Alonso L, Naranjo G, Lucía A, et al. Investigación original Ciento quince pacientes con lupus eritematoso sistémico: características clínicas e inmunológicas. 2015; 1(4):183-92.
15. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006; 119(4).
16. Aroca G, Cadena A, Acosta J. Correlación clínica e inmunohistopatológica de la nefropatía lúpica en un centro de referencia del Caribe colombiano durante los años 2012 a 2013. 2013;
17. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen S Le, et al. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014; 66(2):379-89.
18. López YP, González LA, Restrepo M, Rodríguez LM, León AL, Severiche D, García LF, Vásquez G. Investigación original. Anticuerpos Anti-C1q como marcadores de compromiso renal en pacientes con lupus eritema-toso sistémico. 2013; 20(4):195-201.
19. Ward MM, Pajevic S, Dreyfuss J, Malley JD. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random fo-rests. Arthritis Rheum. 2006; 55(1):74-80.
20. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006; 69(10):1846-51.
21. Pinto Peñaranda LF, Castro Mercado IL, Duque Caballero V, Márquez Hernández JD, Velásquez Franco CJ. Factores de riesgo predictores de falla a la terapia de inducción de nefritis lúpica en una cohorte de pacientes colombianos. Reumatol Clin. 2014; 10(3):147-51.
22. Houssiau F , Vasconcelos C, D’Cruz D, Sebas-tiani GD, De Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the eurolupus nephritis trial. Arthritis Rheum. 2004; 50(12):3934-40.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
